Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022

乳がんリキッドバイオプシーの世界市場予測(~2022年)

◆タイトル:Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022
◆商品コード:MD-6502
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年8月3日
◆ページ数:83
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥615,850見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥724,850見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥888,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、乳がんリキッドバイオプシーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、循環バイオマーカー別分析、エンドユーザー別分析、プラットフォーム比較別(NGS、PCR)分析、競合環境別(M&A、合併、協力、競合技術)分析、乳がんリキッドバイオプシーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Global breast cancer liquid biopsy market projected to grow at a CAGR of 23.1%”The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022. Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.

“Cell-free DNA to register the highest CAGR during the forecast period”
Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.

“Reference laboratories to register the largest share during the forecast period”
Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.

“Asia Pacific to witness the highest growth during the forecast period (2017–2022)”
North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1– 15%, Tier 2– 45%, and Tier 3–40%
• By Designation – C-level– 27%, Director Level–33%, Others–40%
• By Region – North America–25%, Europe–45%, Asia-Pacific–15%, RoW–15%

Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).
Research Coverage:
The report analyzes the breast cancer liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by circulating biomarker, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
• Innovation: Detailed insights on upcoming trends and product launches in the global breast cancer liquid biopsy market
• Market Development: Comprehensive information on the lucrative emerging markets by product, circulating biomarkers, end user, and region
• Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global breast cancer liquid biopsy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy products of leading players in the global market

【レポートの目次】

TABLE OF CONTENTS

1 LIQUID BIOPSY: MARKET AT A GLANCE
1.1 INTRODUCTION
1.2 ISSUES ADDRESSED BY LIQUID BIOPSY & BIOMARKERS DETECTED
1.3 MILESTONES IN LIQUID BIOPSY
2 LIQUID BIOPSY: CIRCULATING BIOMARKERS
2.1 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA (CTDNA)
2.2 CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
2.3 METHODS FOR CTC ISOLATION
3 LIQUID BIOPSY: MARKET OVERVIEW
3.1 INTRODUCTION
3.1.1 DRIVERS
3.1.2.1 HIGH BURDEN OF CANCER
3.1.2.2 INCREASING PREFERENCE FOR NONINVASIVE PROCEDURES
3.1.2.3 INITIATIVES UNDERTAKEN BY GOVERNMENTS
AND GLOBAL HEALTH ORGANIZATIONS
3.1.2.4 TECHNOLOGICAL ADVANCEMENTS
3.1.2.5 RISING EMPHASIS ON PERSONALIZED MEDICINE
3.1.2.6 AVAILABILITY OF FUNDING FOR LIQUID BIOPSY R&D
3.1.2 RESTRAINTS
3.1.2.1 LOW SENSITIVITY AND SPECIFICITY
3.1.3 OPPORTUNITIES
3.1.3.1 GROWING INTEREST IN LIQUID BIOPSY
3.1.4 CHALLENGES
3.1.4.1 UNCLEAR REGULATORY AND REIMBURSEMENT SCENARIO
4 MAJOR INVESTMENTS & INITIATIVES
4.1 GOVERNMENT FUNDING & INITIATIVES
4.2 INDUSTRY INVESTMENTS AND INITIATIVES
5 BREAST CANCER LIQUID BIOPSY MARKET
5.1 BREAST CANCER LIQUID BIOPSY MARKET: GLOBAL SCENARIO
5.2 POTENTIAL OF LIQUID BIOPSY AND CTC IN BREAST CANCER DIAGNOSIS


6 LIQUID BIOPSY MARKET: COMPETITIVE LANDSCAPE
6.1 INTRODUCTION
6.2 KEY STRATEGIES
6.2.1 ACQUISITIONS AND MERGERS
6.2.2 PRODUCT LAUNCHES
6.2.3 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
6.3 LIQUID BIOPSY MARKET: COMPETITIVE TECHNOLOGY PORTFOLIO
7 APPENDIX
7.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
7.2 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
7.3 AVAILABLE CUSTOMIZATIONS
7.4 RELATED REPORTS
7.5 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
TABLE 2 METHODS FOR CTC ISOLATION-1
TABLE 3 METHODS FOR CTC ISOLATION -2
TABLE 4 CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
TABLE 5 UPCOMING CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
TABLE 6 GOVERNMENT FUNDING & INITIATIVES – NORTH AMERICA
TABLE 7 GOVERNMENT FUNDING & INITIATIVES – EUROPE
TABLE 8 GOVERNMENT FUNDING & INITIATIVES – ASIA PACIFIC
TABLE 9 GOVERNMENT FUNDING & INITIATIVES – REST OF THE WORLD
TABLE 10 MAJOR INVESTMENTS IN THE LIQUID BIOPSY MARKET (2010–2017) -1,2,3,4,5,6
TABLE 11 BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER,
2015-2022 (USD MILLION)
TABLE 12 BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2015-2022 (USD MILLION)
TABLE 13 BREAST CANCER LIQUID BIOPSY MARKET, BY END USER,
2015-2022 (USD MILLION)
TABLE 14 BREAST CANCER CTDNA MARKET, BY REGION, 2015-2022 (USD MILLION)
TABLE 15 MAJOR PLAYERS AND COMPETITIVE TECHNOLOGY PORTFOLIO – 1,2,3,4,5,6,7



LIST OF FIGURES

FIGURE 1 ISSUES ADDRESSED BY LIQUID BIOPSY
FIGURE 2 LIQUID BIOPSY: DETECTION OF CANCER BIOMARKERS
FIGURE 3 MILESTONES IN LIQUID BIOPSY
FIGURE 4 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 5 GLOBAL CANCER MORTALITY STATISTICS (2012)
FIGURE 6 BIOMARKERS USED IN CURRENT LIQUID BIOPSY TESTS
FIGURE 7 PUBMED PUBLICATIONS ON LIQUID BIOPSY
FIGURE 8 INVESTMENTS IN LIQUID BIOPSY: 2016 & 2017 (USED MILLION)
FIGURE 9 NGS FUND-RAISING IN 2017 (USD MILLION)
FIGURE 10 BREAST CANCER LIQUID BIOPSY: MARKET OVERVIEW
FIGURE 11 LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKERS (CAGR 2017 – 2022)



★調査レポート[乳がんリキッドバイオプシーの世界市場予測(~2022年)] ( Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022 / MD-6502) 販売に関する免責事項
[乳がんリキッドバイオプシーの世界市場予測(~2022年)] ( Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022 / MD-6502) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆